12:00 AM
 | 
May 28, 2012
 |  BC Week In Review  |  Company News  |  Other News

BioPorto Diagnostics diagnostic news

BioPorto said that the European Patent Office (EPO) rejected the company's European Patent No. EP1831699, covering a method of diagnosing renal disorders by applying a cutoff when measuring the concentration of the lipocalin ( LCN2; NGAL) biomarker. BioPorto and its patent attorney, Suzzane Hoiberg, plan to appeal the decision in late September. The company said the patent will remain valid until a final...

Read the full 316 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >